Climb Bio, Inc. CLYM Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $38.76M+26.8% | $46.71M+226% | $38.93M+238% | $36.1M+344% | $30.57M+184% | ||
| $21.32M+7.7% | $21.17M+32.1% | $20.56M+57.4% | $20.24M+109% | $19.8M+119% | ||
| $60.08M-41.1% | $67.88M-17.2% | $59.5M-22.0% | $56.34M-18.9% | $102.03M+414% | ||
| -$60.08M+41.1% | -$67.88M+17.2% | -$59.5M+22.0% | -$56.34M+18.9% | -$102.03M-414% | ||
| $7.28M-19.5% | $8.03M-1.1% | $8.75M+23.0% | $9.58M+80.6% | $9.05M+70.3% | ||
| -$52.79M+43.2% | -$59.85M+19.0% | -$50.75M+26.6% | -$46.76M+27.2% | -$92.98M-540% | ||
| -$0.77— | -$0.88— | —— | —— | —— | ||
| -$59.94M— | -$67.79M— | -$59.43M— | -$56.3M— | —— | ||
| -$60.08M+41.1% | -$67.88M+17.2% | -$59.5M+22.0% | -$56.34M+18.9% | -$102.03M-414% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Climb Bio, Inc. profitable?
- Climb Bio, Inc. is not currently profitable: it reported a net loss of $52.8M over the trailing twelve months.
- What is Climb Bio, Inc.'s earnings per share?
- Climb Bio, Inc.'s diluted EPS over the trailing twelve months is $-0.77.
- Where does Climb Bio, Inc.'s income statement data come from?
- Every line is extracted from Climb Bio, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.